Clearpoint Neuro Inc - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS

Ticker Exchange SIC # Website Latest Ticker
CLPT Nasdaq 3845 https://www.clearpointneuro.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Clearpoint Neuro Inc

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2022 Results - Mar 1st, 2023 9:05 pm
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2022 Revenue Results March 1, 2023 - Feb 15th, 2023 9:05 pm
ClearPoint Neuro Reports Fourth Quarter and Full Year 2022 Preliminary Revenue Results and Guidance for Full Year 2023 Revenue - Jan 11th, 2023 1:00 pm
ClearPoint Neuro Announces First Patient Enrolled in Glioblastoma Trial Using ClearPoint Prism™ Neuro Laser Therapy System at Skåne University Hospital in Sweden - Dec 12th, 2022 2:15 pm
ClearPoint Neuro to Present at Upcoming Investor Conferences - Nov 9th, 2022 2:25 pm
ClearPoint Neuro Reports Third Quarter 2022 Results - Nov 8th, 2022 9:05 pm
ClearPoint Neuro to Announce Third Quarter 2022 Results November 8, 2022 - Oct 26th, 2022 8:05 pm
ClearPoint Neuro Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System - Sep 23rd, 2022 6:45 am
ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer - Sep 20th, 2022 8:05 pm
ClearPoint Neuro Announces FDA Clearance for Software Version 2.1 - Sep 19th, 2022 8:13 pm
ClearPoint Neuro Reports Second Quarter 2022 Results - Aug 9th, 2022 8:15 pm
ClearPoint Neuro Announces FDA Clearance for ClearPoint Maestro™ Brain Model - Aug 9th, 2022 8:05 pm
ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs - Aug 8th, 2022 8:05 pm
ClearPoint Neuro to Announce Second Quarter 2022 Results August 9, 2022 - Jul 26th, 2022 8:05 pm
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ - First Disease-Modifying Treatment for AADC Deficiency - Jul 21st, 2022 8:20 pm
ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy - Jun 29th, 2022 8:05 pm
ClearPoint Neuro Announces Receipt of MDSAP Certification - Jun 2nd, 2022 8:05 pm
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency - May 20th, 2022 1:29 pm
ClearPoint Neuro to Present Investigational Research and Exhibit at the American Society of Gene & Cell Therapy Annual Meeting in Washington, DC - May 13th, 2022 1:25 pm
ClearPoint Neuro Reports First Quarter 2022 Results - May 11th, 2022 8:05 pm